Published online before print April 15, 2002, doi: 10.1161/01.CIR.0000015699.48605.08
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:2179.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Adverse Neonatal and Cardiac Outcomes Are More Common in Pregnant Women With Cardiac Disease
From the Department of Medicine, Division of Cardiology (S.C.S., J.M.C., J.C.S.), Department of Obstetrics and Gynecology (S.S., D.F., K.S.A., M.S.), and Department of Pediatrics, Division of Cardiology (J.F.S.), University of Toronto, Toronto, Ontario, Canada.
Correspondence to Samuel Siu, MD, Toronto General Hospital, PMCC 3-526, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4. E-mail Sam.Siu{at}uhn.on.ca
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Pregnant women with heart disease (HD) are at increased risk for cardiac (CV) complications. However, the frequency of neonatal (NE) complications in pregnant women with HD relative to pregnant women without HD has not been examined.
Methods and Results— Pregnant women with HD were prospectively monitored during 302 pregnancies. The frequency of NE and CV complications was compared with those in a control group without HD during 572 pregnancies. The frequency of NE complications was higher in the HD group (18% versus 7%; HD versus controls). The NE complication rate was lowest in pregnancies of women age 20 to 35 years who did not smoke during pregnancy, did not receive anticoagulants, and had no obstetric risk factors: 4% in control patients, 5% in HD patients with no cardiac risk factors for NE complications (left heart obstruction, poor functional class, or cyanosis), and 7% in HD patients with 
1 such risk factor. In contrast, the event rate in pregnancies of controls age <20 or >35 years who had obstetric risk factors or multiple gestation or who smoked was 11%. In the HD group, women age <20 or >35 years who had obstetric risk factors or multiple gestation, who smoked, or who received anticoagulants experienced an even higher NE complication rate (27% with no cardiac risks for NE events and 33% in the presence of 1 cardiac risk factors). The frequency of CV complications was higher in the HD group (17% versus 0%; HD versus controls).
Conclusion— Pregnant women with HD are at increased risk for both NE and CV complications. The risk for NE adverse events in pregnant women with HD is highest in those with both obstetric and cardiac risk factors for NE complications.
Key Words: pregnancy • heart disease • prognosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the presence of maternal heart disease, the circulatory changes of pregnancy may result in adverse consequences, including death of the mother or fetus.1–5 Previous studies examining pregnancy outcomes in women with heart disease have focused on maternal cardiac outcomes.1–11 Although neonatal outcomes were reported in previous studies, it is difficult to interpret their findings in the absence of a control group.1,2,4,6,8 The frequency of neonatal complications was likely underestimated because most outcome studies were retrospective.2–4,6,7,9–11 In view of the association between neonatal complications, structural brain abnormalities, and neurocognitive impairment,12–14 it is important to establish the relative risk of neonatal complications in pregnant women with heart disease, as this will help determine the intensity of antepartum surveillance and follow-up of offspring. In the present study, we prospectively examined the frequency of neonatal, obstetric, and cardiac complications in pregnant women with and without heart disease.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study was a preplanned substudy of a multicenter study that examined cardiac outcomes in pregnant women with heart disease.5 The heart disease group consisted of patients prospectively enrolled in the multicenter study from Toronto General, Mount Sinai, and Women’s College hospitals in Toronto (1994 to 1999), meeting the following criteria: pregnant women with structural cardiac lesions or with symptomatic cardiac arrhythmias requiring treatment before pregnancy. Women with isolated mitral valve prolapse (mild mitral regurgitation) were excluded.
The control group consisted of pregnant women prospectively recruited from the general obstetric clinics of the same 3 hospitals during the same time period as the cardiac patients, who received their care from the same obstetricians who cared for the pregnant women with heart disease. For the first 4 years of the study, 2 consecutive controls were recruited for every pregnant woman with heart disease recruited into the study; controls were recruited within 2 weeks of the recruitment of each woman with heart disease. During the last 12 months of the study, funding reduction resulted in the recruitment of 1 control for every woman with heart disease. This study received institutional ethics approval, and subjects gave written informed consent.
Each patient was monitored from the first antenatal visit (baseline) until the sixth postpartum month, using a standardized follow-up schedule and prespecified definitions for data collection. Adverse events were independently verified by 2 physicians unrelated to the study, who were blinded to patient baseline characteristics or group assignment.
The following baseline data were recorded in all patients: age, gestational age, parity status, comorbid conditions (pulmonary disease, thyroid dysfunction, hypertension, diabetes mellitus, or systemic lupus erythematosus), maternal smoking and/or alcohol consumption, maternal educational status (surrogate for socioeconomic status), and recognized obstetric risk factors for neonatal complications (history of premature delivery or rupture of membranes, incompetent cervix, or caesarean section; or intrauterine growth retardation, antepartum bleeding >12 weeks gestation, febrile illness, or uterine/placental abnormalities during present pregnancy).5,15–18
In the heart disease group, the following additional baseline data were recorded: New York Heart Association (NYHA) functional class, prior cardiac events (heart failure, transient ischemic attack, or stroke before present pregnancy; for those who had undergone prior cardiac intervention, only events after the intervention were considered), nature of cardiac lesion or arrhythmia, nature of cardiac intervention, presence of cyanosis (oxygen saturation <90%), use of cardiac medications and anticoagulants, and 12-lead ECG. As previously described, the heart disease group underwent echocardiographic assessment of ventricular systolic function, inflow or outflow obstruction, valvular regurgitation, and systolic pulmonary artery pressure.4,5
Follow-up data were obtained at clinical visits during the second trimester (<28 weeks), third trimester (28 to 37 weeks), peripartum period (onset of labor until hospital discharge), and then at 6 weeks and 6 months postpartum. Newborns of mothers with congenital heart disease were examined for heart disease; pediatric echocardiography was performed in all infants with abnormal cardiac examinations.
Adverse events during the ante-, peri-, and postpartum periods were classified as neonatal, obstetric, or cardiac complications. Neonatal complications were defined as: premature birth (<37 weeks gestation), small-for-gestational-age birth weight (<10th percentile for gestational age), respiratory distress syndrome, intraventricular hemorrhage, fetal death (20 weeks gestation and before birth), or neonatal death (from birth to age 28 days). Obstetric complications were maternal death from noncardiac causes, pregnancy-induced hypertension, or postpartum hemorrhage. Pregnancy-induced hypertension was defined as an increase of 30 mm Hg in systolic blood pressure and 15 mm Hg in diastolic blood pressure compared with baseline values. Postpartum hemorrhage was defined as blood loss >500 mL after vaginal delivery or >1000 mL after caesarean section, requiring transfusion or accompanied by a drop in hemoglobin level of 20 g/L. Cardiac complications were defined as pulmonary edema (documented by chest radiograph or by crackles heard over at least one third of posterior lung fields), sustained symptomatic tachyrhythmia or bradyarrhythmia requiring treatment, stroke, cardiac arrest, or cardiac death.
Data Analysis
Each pregnancy was treated as a separate data unit. Baseline characteristics and complication rates in pregnancies not ending in miscarriage were compared between heart disease and control groups by 
2, Fisher’s exact, and t tests wherever appropriate. Comparative risk for neonatal events between heart disease and control groups was adjusted for baseline differences in clinical, socioeconomic, and obstetric characteristics by multivariate logistic regression analysis, which accounted for the fact that some women underwent >1 pregnancy.19
To examine the relationship between baseline maternal characteristics and neonatal event rate, the total patient sample was divided into 2 groups by the presence or absence of major noncardiac maternal factors previously shown to be associated with increased neonatal risk (including the recognized obstetric characteristics as defined earlier and maternal age <20 or >35 years, use of anticoagulation during pregnancy, smoking, and multiple gestation).5,15–18 Within each group, neonatal event rates were compared between the control women and the women with heart disease. The women with heart disease were further subdivided into those with and without cardiac risk factors shown by us and others to be associated with neonatal complications (maternal NYHA functional class III/IV, cyanosis, or left heart obstruction as defined by mitral valve area <2 cm2, aortic valve area <1.5 cm2, or peak left ventricular outflow tract gradient >30 mm Hg).1,2,4–6,20
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Follow-up was completed in all patients in March 2000. Three hundred one pregnant women with heart disease were enrolled during 334 pregnancies, and simultaneously, 572 pregnant women without heart disease were enrolled during 578 pregnancies. The frequency of miscarriage and termination was significantly higher in the heart disease group (Figure 1). To adjust for differences in baseline gestational age, the miscarriage rate was also compared for those pregnancies in which the patient presented at >12 weeks gestation. When only pregnancies meeting this criterion were analyzed, there was still a trend to increased miscarriage in the heart disease group (P=0.09). The proportion of terminations performed for cardiac, medical, or genetic indications in the HD and control groups were 68% and 100%, respectively (P=0.46).
|
Overall, 90% and 99% of pregnancies in the heart disease and control groups, respectively, progressed beyond 20 weeks of gestation (completed pregnancies); the age distribution and parity status of the heart disease and control groups were comparable (Table 1). The number of pregnancies with comorbid conditions, obstetric risk factors for neonatal complications, or in which the mother continued to smoke during pregnancy was higher in the heart disease group. A higher proportion of women in the control group had attained college, university, or a trade certificate as their highest educational level (Table 1).
|
In the heart disease group, the principal maternal cardiac lesion was congenital in 194 (64%), acquired in 85 (28%), and arrhythmic in 23 (8%) pregnancies. Nature of the principal maternal cardiac lesion and baseline cardiac status are summarized in Table 2. In 123 pregnancies (41%), the mother had undergone 1 of the following surgical interventions before conception: closure of cardiac shunts (n=46), coarctation repair (n=19), repair of complex congenital lesion (tetralogy of Fallot or double outlet right ventricle [n=23], Mustard repair [n=12], Rastelli repair [n=3], or Fontan repair [n=3]), valve repair (n=14), prosthetic valve replacement (mechanical [n=8], tissue [n=11], or pulmonary autograft [n=3]), reimplantation of left coronary artery (n=1), resection of subaortic stenosis (n=1), heart-lung transplantation (n=1), or resection of atrial myxoma (n=1).
|
The caesarean rate was higher in the heart disease group (Table 3). Six caesarean deliveries were performed for a cardiac indication in the heart disease group, in contrast to none in the control group. There were no significant differences between the 2 groups in the proportion of caesarean deliveries performed as a result of failure to progress, fetal distress, breech presentation, or prior caesarean section.
|
The frequency of neonatal complications in the heart disease group was more than twice that of controls (Table 3). For each type of neonatal event (premature birth, small for gestational age birth weight, respiratory distress syndrome or intraventricular hemorrhage, fetal/neonatal death) the event rate was higher in the heart disease group (Figure 2 and Table 3). Five of 6 neonatal deaths were in premature newborns; the other death was in a newborn with small-for-gestational-age birth weight.
|
Maternal heart disease was associated with an increased risk of neonatal complications, even when baseline differences in clinical, cardiac, socioeconomic, and obstetric risk profile between the 2 groups were accounted for (odds ratio, 2.3; 95% confidence interval, 1.4 to 4.0; P=0.006). The frequency of the most serious NE complications (intraventricular hemorrhage, delivery before 34 weeks, or neonatal/fetal death) was also higher in the heart disease (6%) group than in the control (2%) group (P=0.002).
The frequency of neonatal complications was lowest in singleton pregnancies in women age 20 to 35 years who did not smoke during pregnancy, did not receive anticoagulants during pregnancy, and had no obstetric risk factors: 4% in control patients, 5% in heart disease patients with no cardiac risk factors for NE complications (left heart obstruction or poor functional class/cyanosis), and 7% in heart disease patients with 1 such risk factor (P=0.41). In contrast, the event rate in pregnancies of controls age <20 or >35 years who had obstetric risk factors or multiple gestation or who smoked was 11%. In the heart disease group, women <20 or >35 years of age who had obstetric risk factors, who had multiple gestation, who smoked, or who received anticoagulants demonstrated a neonatal complication rate even higher (27% with no cardiac risks for NE events and 33% with 1 of these cardiac risk factors; P<0.001) (Figure 3).
|
Congenital heart disease was seen in the offspring in 8% of the 183 live births resulting from pregnancies in mothers with congenital heart disease but not part of a recognized genetic syndrome (atrial or ventricular septal defect [n=14], pulmonic stenosis [n=1]).
The frequency of postpartum hemorrhage and pregnancy-induced hypertension was not significantly different between heart disease and control groups (Table 3). There was no significant difference between the groups when a more recent criterion for pregnancy-induced hypertension (blood pressure 140/90 after 20 weeks of gestation) was used (5% and 3%, heart disease and controls; P=0.72). There was 1 noncardiac death (postpartum depression and suicide in a woman with atrial septal defect).
Fifty-two completed pregnancies (17%) in the heart disease group were complicated by a cardiac event (Table 3); heart failure or cardiac arrhythmia accounted for most of the cardiac outcomes (94%). Embolic strokes complicated pregnancy in 3 women; 1 each with dilated cardiomyopathy, mechanical valve replacement with suboptimal anticoagulation, and transposition of the great arteries with Mustard procedure with severe systemic ventricular systolic dysfunction. The woman with Mustard procedure who had a stroke succumbed because of postpartum heart failure. The other postpartum cardiac death occurred in a mother with severe pulmonary hypertension. Maternal stroke or cardiac death complicated 4 pregnancies (1%). The maternal cardiac complications have been reported previously in detail as part of the larger national study.5 There were no cardiac complications in the control group (P<0.001 versus heart disease group).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this contemporary cohort of pregnant women receiving comprehensive perinatal care, pregnant women with heart disease are at increased risk for neonatal and cardiac complications. In women without obstetric risk factors for neonatal adverse events, the incremental risk of neonatal complications associated with the presence of maternal heart disease was small. However, in those with heart disease and concurrent obstetric risk factors, the risk of neonatal complications was considerably higher than that in controls with similar obstetric risk factors.
Previous studies examining pregnant women with heart disease have reported high rates of neonatal complications.1,2,4,6,8,20 It is difficult to apply their findings, however, because they examined patients from an earlier era and/or used data collected retrospectively. In virtually all these previous studies, the increase in neonatal risk associated with pregnancy in women with heart disease was assumed. In the single study in which outcomes from retrospectively selected controls were examined, pregnant women with valvular heart disease had a significantly higher neonatal complication rate than that of controls.20 Our study extends the results of previous studies by quantifying the relative risk associated with heart disease in a large group of pregnant women with a wide spectrum of cardiac lesions who were receiving modern obstetric and cardiac care, while adjusting for the effects of baseline cardiac and obstetric characteristics. Prospective enrollment of both the heart disease and control groups, who received obstetric care in the same hospitals and during the same time period, minimized the potential confounding influence of local practice patterns or changes in practice patterns over time. Unlike previous studies that have focused only on fetal death, premature birth, or small-for-gestation-age birth weight,1,2,4,6,8 we were able to prospectively assess all clinically important neonatal complications, including respiratory distress syndrome and intraventricular hemorrhage.
Previous studies have reported that poor maternal functional class, cyanosis, and left heart obstruction were associated with neonatal complications in pregnant women with heart disease.1,2,4–6 The present study unifies prior study findings by demonstrating the interaction between baseline cardiac and obstetric characteristics in determining neonatal complications. For example, even in the presence of cardiac risk factors such as left heart obstruction, poor functional class, or cyanosis, the neonatal complication rate in the heart disease group was only minimally increased from that of controls if the mother did not have other maternal risk factors. On the other hand, if the mother had concurrent maternal risk factors, the neonatal complication rate in the heart disease group was more than twice that of controls with similar maternal risk factors. Women in this group with maternal cardiac risk factors for neonatal events experienced the highest neonatal complication rate.
There are several possible reasons for the increased rate of neonatal complications in pregnant women with heart disease. The relationship between maternal cyanosis and fetal growth has been well defined; maternal oxygen saturation is inversely related to birth weight and fetal mortality.6,21 The effect of functional class and left heart obstruction on preterm delivery, fetal death, and growth retardation is likely mediated by uteroplacental insufficiency. Indeed, fetal cardiac contractility and output are adversely affected by hypoxic academia resulting from uteroplacental insufficiency.22,23 The increased rate of premature birth in the heart disease group cannot be attributed to a more aggressive strategy of preterm induction in this group, as the rate of spontaneous premature onset of labor resulting in preterm delivery was also significantly higher in the heart disease group than in control groups. Thus, the effect of both obstetric and cardiac risk factors may be manifested as a higher risk of premature labor. Indeed, we previously observed an association between antenatal cardiac complications and the onset of premature labor.4 The higher rate of small-for-gestational-age birth weight infants did not reach statistical significance, perhaps as a result of the overriding effects of preterm births; a higher frequency might have been observed if more pregnancies had progressed toward term. Alternatively, provision of modern antenatal care and universal access to obstetric care may have resulted in a lower incidence of intrauterine growth retardation than previously reported.
We examined other neonatal outcomes such as respiratory distress syndrome and intraventricular hemorrhage in addition to prematurity, low birth weight, and death. The relationship between prematurity and small-for-gestational age birth weight, and neurocognitive abnormalities is well described.12–14,24 However, respiratory distress syndrome and intraventricular hemorrhage are also associated with developmental delay and cognitive impairment.25–28 By more completely assessing the risk of neonatal complications, the present study identified those neonates who are at risk for neurocognitive impairment and are therefore candidates for more intensive follow-up and therapeutic strategies.
A key study finding was that the deleterious effects of maternal heart disease on neonatal outcomes were amplified by the presence of concurrent obstetric risk factors for neonatal complications. This relationship between maternal status and neonatal outcomes has not been previously reported, likely because previous studies have either not examined obstetric risk factors or lacked sufficient patient numbers. Future investigations will need to define the mechanisms underlying our observations, analogous to the approach used in analyzing the relationship between maternal diabetes and congenital cardiac malformations.29–30 Furthermore, clinicians will be reminded of the need to optimize obstetric and cardiac status in pregnant women with heart disease. The importance of smoking cessation may need special emphasis in women with heart disease who are considering pregnancy.
Our study was not designed to provide lesion-specific comparisons of risk. However, in previous studies from our center and others, left heart obstruction, poor functional class, and cyanosis have predicted neonatal complications.1,2,4–7 Only by examining patients with a spectrum of cardiac lesions and risk profiles have we been able to define the interaction between maternal cardiac status, obstetric risk factors, and neonatal complications. Selection bias was minimized by the fact that participating centers provide primary and referral obstetric care for the metropolitan Toronto area. We chose to adjust for baseline differences between heart disease and control groups at the time of analysis, as it was not possible to match the groups in all baseline characteristics. However, the 2 groups were similar in regard to maternal age and parity status. Universal access to obstetric care and the use of a standardized obstetric follow-up schedule in the province of Ontario likely reduced the effect of socioeconomic status on neonatal outcomes.
In conclusion, the increased risk of neonatal complications in pregnant women with heart disease is amplified by the presence of obstetric risk factors. Women with heart disease who are age <20 or >35 years or who exhibit maternal obstetric or cardiac risk factors require increased intensity of antepartum surveillance. These women likely will benefit from referral to a regional center for care during their pregnancy. Conversely, women with heart disease without cardiac or obstetric risk factors are at minimally increased risk compared with pregnant women without heart disease and likely do not require increased intensity of antepartum surveillance.
|
Acknowledgments |
|---|
This study was supported by operating grants from the PSI Foundation (09420) and the Medical Research Council of Canada (MT13216).
Received January 10, 2002; revision received February 27, 2002; accepted February 28, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Whittemore R, Hobbins J, Engle M. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol. 1982; 50: 641–651.
2. Shime J, Mocarski E, Hastings D, et al. Congenital heart disease in pregnancy: short- and long-term implications. Am J Obstet Gynecol. 1987; 156: 313–322.
3. McFaul P, Dornan J, Lamki H, et al. Pregnancy complicated by maternal heart disease: a review of 519 women. Br J Obstet Gynaecol. 1988; 95: 861–867.
4. Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation. 1997; 96: 2789–2794.
5. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; 104: 515–521.
6. Presbitero P, Somerville J, Stone S, et al. Pregnancy in cyanotic congenital heart disease: outcome of mother and fetus. Circulation. 1994; 89: 2673–2676.
7. Connolly H, Warnes C. Ebstein’s anomaly: outcome of pregnancy. J Am Coll Cardiol. 1994; 23: 1194–1198.
8. Canobbio M, Mair D, van der Velde M, et al. Pregnancy outcomes after the Fontan repair. J Am Coll Cardiol. 1996; 28: 763–767.
9. Connolly HM, Grogan M, Warnes CA. Pregnancy among women with congenitally corrected transposition of great arteries. J Am Coll Cardiol. 1999; 33: 1692–1695.
10. Genoni M, Jenni R, Hoerstrup SP, et al. Pregnancy after atrial repair for transposition of the great arteries. Heart. 1999; 81: 276–277.
11. Zuber M, Gautschi N, Oechslin E, et al. Outcome of pregnancy in women with congenital shunt lesions. Heart. 1999; 81: 271–275.
12. Stewart AL, Rifkin L, Amess PN, et al. Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm. Lancet. 1999; 353: 1653–1657.
13. Peterson BS, Vohr B, Staib LH, et al. Regional brain volume abnormalities and long-term cognitive outcome in preterm infants. JAMA. 2000; 284: 1939–1947.
14. Hack M, Taylor HG. Perinatal brain injury in preterm infants and later neurobehavioral function. JAMA. 2000; 284: 1973–1974.
15. Moutquin JM, Gagnon R, Rainville C, et al. Maternal and neonatal outcome in pregnancies with no risk factors. CMAJ. 1987; 137: 728–732.
16. Creasy RK, Gummer BA, Liggins GC. System for predicting spontaneous preterm birth. Obstet Gynecol. 1980; 55: 692–5.
17. Ross MG, Hobel CJ, Bragonier JR, et al. A simplified risk-scoring system for prematurity. Am J Perinatol. 1986; 3: 339–344.
18. Holbrook RH Jr, Laros RK Jr, Creasy RK. Evaluation of a risk-scoring system for prediction of preterm labor. Am J Perinatol. 1989; 6: 62–68.
19. Zeger S, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42: 121–130.
20. Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol. 2001; 37: 893–899.
21. Whittemore R. Congenital heart disease: its impact on pregnancy. Hosp Pract. 1983; 18: 65–74.
22. Rizzo G, Arduini D. Fetal cardiac function in intrauterine growth retardation. Am J Obstet Gynecol. 1991; 165: 876–882.
23. Lewinsky RM, Szwarc RS, Benson LN, et al. The effects of hypoxic acidemia on left ventricular end-systolic elastance in fetal sheep. Pediatr Res. 1993; 34: 38–43.
24. Breslau N, DelDotto JE, Brown GG, et al. A gradient relationship between low birth weight and IQ at age 6 years. Arch Pediatr Adolesc Med. 1994; 148: 377–383.
25. Piper MC, Kunos I, Willis DM, et al. Effect of gestational age on neurological functioning of the very low- birthweight infant at 40 weeks. Dev Med Child Neurol. 1985; 27: 596–605.
26. Dunn HG, Crichton JU, Grunau RV, et al. Neurological, psychological and educational sequelae of low birth weight. Brain Dev. 1980; 2: 57–67.
27. Stewart A, Hope PL, Hamilton P, et al. Prediction in very preterm infants of satisfactory neurodevelopmental progress at 12 months. Dev Med Child Neurol. 1988; 30: 53–63.
28. Hack M, Taylor HG, Klein N, et al. School-age outcomes in children with birth weights under 750 g. N Engl J Med. 1994; 331: 753–759.
29. Gladman G, McCrindle BW, Boutin C, et al. Fetal echocardiographic screening of diabetic pregnancies for congenital heart disease. Am J Perinatol. 1997; 14: 59–62.
30. Ferencz C, Rubin JD, McCarter RJ, et al. Maternal diabetes and cardiovascular malformations: predominance of double outlet right ventricle and truncus arteriosus. Teratology. 1990; 41: 319–326.
This article has been cited by other articles:
 |
|
 |
|
  S. Tsiaras and A. Poppas Mitral valve disease in pregnancy: outcomes and management Obstet Med, March 1, 2009; 2(1): 6 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chandrasekhar, C. R. Cook, and C. D. Collard Cardiac Surgery in the Parturient Anesth. Analg., March 1, 2009; 108(3): 777 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 2, 2008; 52(23): e143 - e263. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, December 2, 2008; 118(23): e714 - e833. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, December 2, 2008; 118(23): 2395 - 2451. [Full Text] [PDF]
|
|
|
|
|
|
2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Stangl, J. Schad, G. Gossing, A. Borges, G. Baumann, and K. Stangl Maternal heart disease and pregnancy outcome: A single-centre experience Eur J Heart Fail, September 1, 2008; 10(9): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bedard, D. F. Shore, and M. A. Gatzoulis Adult congenital heart disease: a 2008 overview Br. Med. Bull., March 1, 2008; 85(1): 151 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Thangaroopan, R. M. Wald, C. K. Silversides, J. Mason, J. F. Smallhorn, M. Sermer, J. M. Colman, and S. C. Siu Incremental Diagnostic Yield of Pediatric Cardiac Assessment After Fetal Echocardiography in the Offspring of Women With Congenital Heart Disease: A Prospective Study Pediatrics, March 1, 2008; 121(3): e660 - e665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K Stout and C. M Otto Pregnancy in women with valvular heart disease Heart, May 1, 2007; 93(5): 552 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Uebing, P. J Steer, S. M Yentis, and M. A Gatzoulis Pregnancy and congenital heart disease BMJ, February 18, 2006; 332(7538): 401 - 406. [Full Text] [PDF]
|
|
|
|
|
|
U. Elkayam, M. W. Akhter, H. Singh, S. Khan, F. Bitar, A. Hameed, and A. Shotan Pregnancy-Associated Cardiomyopathy: Clinical Characteristics and a Comparison Between Early and Late Presentation Circulation, April 26, 2005; 111(16): 2050 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Veldtman, H. M. Connolly, M. Grogan, N. M. Ammash, and C. A. Warnes Outcomes of pregnancy in women with tetralogy of fallot J. Am. Coll. Cardiol., July 7, 2004; 44(1): 174 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Child Fallot's tetralogy and pregnancy: Prognostication and prophesy J. Am. Coll. Cardiol., July 7, 2004; 44(1): 181 - 183. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Arafeh and Y. Y. El-Sayed Cardiac Disease in Pregnancy NeoReviews, June 1, 2004; 5(6): e232 - e239. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Redberg and N. B. Schiller Gender and valvular surgery J. Thorac. Cardiovasc. Surg., January 1, 2004; 127(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Reimold and J. D. Rutherford Valvular Heart Disease in Pregnancy N. Engl. J. Med., July 3, 2003; 349(1): 52 - 59. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||